Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05596708 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05596708 · ClinicalTrials.gov record · last posted 2023-02-24

Study of Telitacicept in Patients With Refractory IgA Nephropathy

StatusNot Yet Recruiting
PhasePhase 2/3
Started2023-03-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 24, 2023 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The goal of this clinical trial is to explore the effectiveness and safety of Telitacicept in adults with refractory IgA nephropathy. The main questions it aims to answer are: * To evaluate the clinical efficacy of Telitacicept in patients with refractory IgA nephropathy. * To evaluate the safety and adverse reaction of Telitacicept in patients with refractory IgA nephropathy. Participants will be subcutaneously injected with 240mg of Telitacicept once per week. Study subject: After 6 months of sequential treatment with renin-angiotensin system (RAS) blockers or glucocorticoids, patients with pathological biopsy of 0.7≥5 g/24 hours of proteinuria was confirmed as refractory IgA nephropathy.

Protocol amendment history 1 change detected by DataLookout

2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
WasSecond Affiliated Hospital, School of Medicine, Zhejiang University
NowSecond Affiliated Hospital, Zhejiang University, School of Medicine
Trial Details
NCT Number NCT05596708
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions IgA Nephropathy
Enrollment 40 participants
Start Date 2023-03-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-02-24